Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride
Author:
Affiliation:
1. Department of Internal Medicine; Seoul National University Hospital; Seoul Korea
2. Department of Internal Medicine; Seoul National University Bundang Hospital; Seongnam Gyeonggi-do Korea
Funder
Innovative Research Institute for Cell Therapy
Korean Diabetes Association
Publisher
Wiley
Subject
General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdi.12572/fullpdf
Reference42 articles.
1. Hypoglycemia, diabetes, and cardiovascular events;Desouza;Diabetes Care,2010
2. Clinical implications of glucose variability: chronic complications of diabetes;Jung;Endocrinol Metab (Seoul),2015
3. Atherosclerosis-an inflammatory disease;Ross;New Engl J Med,1999
4. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action;Drucker;Diabetes Care,2007
5. Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?;Monnier;Diabetes Technol Ther,2012
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Picroside Ⅱ alleviates renal fibrosis through YY1-dependent transcriptional inhibition of TGFβ1;Metabolism Open;2024-09
2. Teneligliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells;Diabetes, Metabolic Syndrome and Obesity;2023-04
3. Decreased Serum Dickkopf-1 Levels After Hypoglycemic Therapy in Patients with Type 2 Diabetes Mellitus;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2022-09
4. Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials;Frontiers in Endocrinology;2022-08-09
5. Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients;Frontiers in Immunology;2022-07-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3